Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

Caitlin E. Cox

February 02, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome

Caitlin E. Cox

October 04, 2024

News Daily News

Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss

Michael O'Riordan

July 23, 2024

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2026

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Top General Cardiology and Prevention News of 2024

Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome

Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Top General Cardiology and CVD Prevention News of 2023

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content